Published in Oncotarget on October 06, 2015
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc (2006) 6.24
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol (2004) 3.33
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell (2006) 3.29
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet (1994) 3.17
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A (1993) 3.07
The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol (1993) 2.84
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet (1988) 2.42
A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene (1995) 2.26
DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol (1994) 2.18
Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene (2009) 2.17
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res (2005) 2.09
The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem (1997) 1.98
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.96
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med (2007) 1.82
NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res (2006) 1.80
A new member of the ETS family fused to EWS in Ewing tumors. Oncogene (1997) 1.79
A molecular function map of Ewing's sarcoma. PLoS One (2009) 1.69
Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res (1996) 1.65
Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res (1998) 1.64
Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene (2010) 1.62
The insulin-like growth factor system and sarcomas. J Pathol (2009) 1.57
Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res (2006) 1.57
Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet (1999) 1.57
Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst (2011) 1.55
EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res (1993) 1.52
NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res (2010) 1.52
Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene (1995) 1.51
FUS/ERG gene fusions in Ewing's tumors. Cancer Res (2003) 1.50
The genomic landscape of pediatric Ewing sarcoma. Cancer Discov (2014) 1.46
Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest (1990) 1.44
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer (2008) 1.35
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem (2003) 1.34
Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn (2007) 1.31
Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res (2004) 1.25
Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer (1996) 1.24
Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene (2012) 1.20
Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene (2003) 1.15
Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma. Cell Cycle (2006) 1.14
Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol (2008) 1.12
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer (2002) 1.09
Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther (2002) 1.09
The molecular pathogenesis of Ewing's sarcoma. Cancer Biol Ther (2010) 1.07
Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget (2012) 1.04
STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res (2011) 1.02
Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. Int J Cancer (2012) 1.01
Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer (2001) 1.00
Inhibition of notch signaling induces neural differentiation in Ewing sarcoma. Am J Pathol (2007) 0.98
IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors (2010) 0.98
Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells. J Cancer Res Clin Oncol (1992) 0.94
Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. Semin Diagn Pathol (1996) 0.92
R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One (2011) 0.92
Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth. Cancer Res (2012) 0.92
BIRC5 expression is a poor prognostic marker in Ewing sarcoma. Pediatr Blood Cancer (2012) 0.89
Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma. Strahlenther Onkol (2012) 0.87
The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I. Thymus (1991) 0.80
Bidirectionality and transcriptional activity of the EWSR1 promoter region. Oncol Rep (2009) 0.76